Molchan S E, Mellow A M, Lawlor B A, Weingartner H J, Cohen R M, Cohen M R, Sunderland T
Unit on Geriatric Psychopharmacology, National Institute of Mental Health, Bethesda, MD 20892.
Psychopharmacology (Berl). 1990;100(1):84-9. doi: 10.1007/BF02245795.
The brain tripeptide thyrotropin-releasing hormone (TRH) has been demonstrated to facilitate cholinergic neurotransmission. To test its interaction with the cholinergic system in humans, high-dose TRH (0.5 mg/kg) or placebo was administered intravenously (IV) to normal controls pretreated with scopolamine (0.5-0.75 mg IV), a centrally active muscarinic antagonist, which has been used to model aspects of the memory impairment of normal aging and of dementia. Compared to placebo, TRH markedly attenuated scopolamine-induced impairment of some measures of memory, most notably on a selective reminding task. This cognitive study is the first in humans to suggest a neuromodulatory effect of a peptide on the cholinergic system, and suggests a facilitatory role for TRH in human memory processes.